Key facts
- It has raised $1.7M; the latest was Early Stage VC ($870K) in Mar 2026.
- Notable investors include Navigare Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ProteomEdge
- ·The full record, as it builds
Funding rounds
No funding rounds for ProteomEdge are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProteomEdge
Developer of integrated bioinformatics platforms designed to facilitate proteomics data analysis and interpretation. The company's platform includes tools for data processing, visualization, and statistical analysis, enabling researchers and scientists in life sciences to efficiently manage complex datasets and derive meaningful biological insights.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2019
- Employees
- 7
- Website
- proteomedge.com/
- Ownership
- Privately Held (backing)
ProteomEdge doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProteomEdge shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProteomEdge in its N-PORT filings yet. We sweep new filings monthly.